This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2020-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2022
Title: Innovations of Craig T Przysiecki
Introduction
Craig T Przysiecki is an accomplished inventor based in Kintnersville, PA (US). He has made significant contributions to the field of biotechnology, particularly in the area of recombinant protein expression. With a total of 2 patents to his name, Przysiecki's work has implications for pharmaceutical applications.
Latest Patents
One of his latest patents focuses on the recombinant expression of major outer membrane protein (MOMP). This invention involves methods for transforming host cells with an expression vector that encodes MOMP and a leader sequence for targeting the protein to the outer membrane of the cell. The innovative method allows for the expression of MOMP in a manner that promotes proper protein folding, making it more similar to native MOMP compared to intracellularly expressed variants. The recombinant MOMP has potential uses in pharmaceutical compositions and methods for treating infections.
Career Highlights
Craig T Przysiecki is currently associated with Merck Sharp & Dohme Corp., where he continues to advance his research in biotechnology. His work has been instrumental in developing methods that enhance the efficacy of protein expression, which is crucial for therapeutic applications.
Collaborations
Przysiecki has collaborated with notable colleagues, including Lan Zhang and Zhiyun Wen. These partnerships have contributed to the success of his research and the development of innovative solutions in the field.
Conclusion
Craig T Przysiecki's contributions to biotechnology through his patents and work at Merck Sharp & Dohme Corp. highlight his role as a key innovator in the field. His research continues to pave the way for advancements in pharmaceutical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
